Alpha-1 Antitrypsin Deficiency Market Booms to US$10 Billion by 2033, Propelled by a Noteworthy 12.8% CAGR | FMI Report

The global Alpha-1 Antitrypsin Deficiency market is poised to achieve a market value of US$3 billion in 2023, with projections indicating a remarkable growth to US$10 billion by 2033, driven by a substantial CAGR of 12.8% during the forecast period. The surge in respiratory illnesses plays a pivotal role in expanding the market. Furthermore, the increasing adoption of augmentation therapy is a key driver of this growth.

Augmentation therapy involves the extraction of AAT protein from healthy donors’ blood plasma to enhance AAT levels in patients’ respiratory tracts. This treatment not only hinders the progression of emphysema but also reduces the frequency of exacerbations and accelerates recovery time. These factors contribute to its rising popularity among patients and healthcare professionals alike.

Research and development (R&D) investments are also projected to have a substantial impact on the sector. Several companies are attempting to create a game-changing portfolio by leveraging in-house competencies and expanding those capabilities through strategic alliances, R&D expansion, and future licensing, merger, and acquisition activities.

Sample PDFs: Your Gateway to Limitless Learning Possibilities. @
https://www.futuremarketinsights.com/reports/sample/rep-gb-16288

Key Takeaways from the Market Study

• The global alpha-1 antitrypsin insufficiency market is expected to develop at a 12.8% CAGR by 2033, according to FMI.
• The global market for Alpha-1 Antitrypsin Deficiency is anticipated to be over US$ 3 billion.
• The global market for Alpha-1 Antitrypsin Deficiency is expected to be around US$ 10 billion.
• According to Future Market Insights, Asia Pacific will grow at a CAGR of 12% between 2023 and 2033.
• North America is expected to grow at a 12.7% CAGR between 2023 and 2033.
• Europe is expected to grow at a 12.3% CAGR between 2023 and 2033.

“Within North America, the United States has dominated the market. The rising number of government funding, developments in gene therapy research and development, and the rising penetration of target illnesses are the primary drivers driving the Alpha-1 Antitrypsin Deficiency market expansion,” says an analyst at FMI

Market Competition

To address the present patient pool’s requests and counter the therapeutic market’s unmet needs, drug developers are increasingly moving their focus to alpha-1 antitrypsin deficiency (AATD).

Many novel medicines are being developed by several businesses, including ARO-AAT (Arrowhead Pharmaceutical), Alvelestat (Mereo Biopharma), and Inhaled AAT (Kamada).

ARO-AAT (Arrowhead Pharmaceutical) is a second-generation subcutaneously given drug that lowers hepatic synthesis of the mutant AAT protein by knocking down the alpha-1 antitrypsin (AAT) gene transcript. The business is now undertaking Phase II clinical studies to assess the drug’s safety, tolerability, and pharmacodynamic impact in AATD patients.

Elevate your understanding with our insightful methodology now. @
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16288

Key players in the Alpha-1 Antitrypsin Deficiency (A1ATD) market are:

1. Pfizer
2. Baxter
3. AstraZeneca
4. Grifols
5. Teva Pharmaceutical Industries
6. BoehringerIngelheim
7. Kamada Ltd
8. GlaxoSmithKline
9.  CSL Behring
10. LFB Biomedicaments

Recent Developments:

Kamada Ltd., a vertically integrated global biopharmaceutical company focused on specialty plasma-derived therapeutics, announced in October 2022 that it had been awarded a three-year extension of an existing tender from the Canadian Blood Services (CBS) for the supply of four IgG products, CYTOGAM®, HEPAGAM®, VARIZIG®, and WINRHO® SDF, for a total estimated value of US$ 22 million. This award ensures that such products will continue to be sold in Canada. In November 2021, Kamada purchased four commercial pharmaceuticals that have been licensed by Health Canada and the United States Food and Drug Administration (FDA).

Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/16288

Key Segments Profiled in the Alpha-1 Antitrypsin Deficiency Market Industry Survey

By Product Type:

• Augmentation Therapy
• Bronchodilators
• Corticosteroids
• Oxygen Therapy

By Application:

• Hospitals
• Specialty Clinics
• Pharmacies

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube